## OMCL: Omnicell, Inc. - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_20 at 11.6% exceeds exhaustion threshold (10.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops.

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($39.73)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_20 drops below exhaustion threshold

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Benchmark raises Omnicell stock price target to $50 on new Titan XT system**
- Source: Investing.com | 20251210T130939 | Bullish | Relevance: 98%
-  Benchmark has increased its price target for Omnicell (NASDAQ:OMCL) to $50 from $45, reiterating a Buy rating after the company unveiled its new Titan XT enterprise medication dispensing system. The company's stock has seen a 13% gain in the past week and a 37% surge over the last six months, with net income expected to grow this year. The Titan XT system, integrating with Omnicell's cloud-based OmniSphere, is set to be priced at a premium, with modest revenue expected in late 2026 and significant financial impact in 2027.

**2. Pharmacy Automation Systems Market to Reach US$ 12.05 Billion**
- Source: openPR.com | 20251210T090916 | Somewhat-Bullish | Relevance: 96%
-  The global Pharmacy Automation Systems Market, valued at US$ 6.95 billion in 2024, is projected to reach US$ 12.05 billion by 2033, growing at a CAGR of 7.0%. This growth is driven by the increasing adoption of automation in healthcare to improve accuracy, streamline workflows, and reduce operational burdens in pharmaceutical environments. North America currently leads the market with a 46% share, while key players include Arxium, BD, Omnicell, and Parata.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Benchmark | $50 | $45 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Benchmark | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 7 ($1.16M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 58.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Blackrock Inc.: 17.1% (-2.3%)
- Vanguard Group Inc: 12.5% (-0.4%)
- Dimensional Fund Adv: 5.3% (+9.1%)
- Cadian Capital Manag: 4.7% (+25.9%)
- State Street Corpora: 4.6% (-2.0%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +3.5% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 2.28 elevated, pricing in significant growth expectations. Forward P/E 23.5x stretched relative to 8% growth. Analyst sentiment positive (1 raises, avg +11%). Insider selling cluster ($1.2M in 90 days), potential headwind. Institutional flow bullish (3 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.0B |
| Beta | 0.83 |
| 52W Range | $22.66 - $47.69 |
| Short Interest | 7.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.28 |
| Forward P/E | 23.5 |
| Current P/E | 25.3 |
| YoY Growth | 7.5% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from 8.2% to 11.6% (+3.5% in 5 days), confirming momentum buildup. Extended beyond STRENGTH zone (11.6% > 10.0%), caution on chasing. MRS_5 at 0.8% confirms short-term momentum alignment. AM_20 at 13.9% shows strong absolute momentum above own 20MA. Outperforming sector by 13.9pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.59), confirming momentum. RSI overbought at 74, risk of mean reversion. Elevated volume (1.5x 20MA), institutional activity likely.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 11.63% (CS: 96) | Strong |
| RSI_14 | 74.2 | Overbought |
| MACD Histogram | 0.59 | Bullish |
| vs SMA20 | 1.139x | Above |
| vs SMA50 | 1.258x | Above |
| vs SMA200 | 1.356x | Above |

### Decision

- **Verdict:** SELL
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $43.29
- **Stop Loss:** $39.73 (8.2% risk)
- **Target:** $46.85 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 387
- **Position Value:** $16,753.23
- **Portfolio %:** 16.75%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-05 (Est: $0.49)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.36 | $0.51 | +40.7% |
| 2025Q2 | $0.27 | $0.45 | +66.7% |
| 2025Q1 | $0.20 | $0.26 | +27.1% |
| 2024Q4 | $0.58 | $0.60 | +2.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*